"The effect of 48-weeks azithromycin therapy on levels of soluble biomarkers associated with HIV-associated chronic lung disease".
Hameiri-Bowen D., Yindom L-M., Sovershaeva E., Bandason T., Mayini J., M Rehman A., Simms V., Gift Ngwira L., Flagestad T., Jarl Gutteberg T., McHugh G., Abbas Ferrand R., Rowland-Jones SL.
OBJECTIVES: HIV-associated immune activation contributes to chronic lung disease (CLD) in children and adolescents living with HIV. Azithromycin has immunomodulatory and anti-microbial properties that may be useful for treating HIV-associated CLD (HCLD). This study describes the effect of azithromycin on expression of plasma soluble biomarkers in children and adolescents with HCLD. METHODS: This study was nested within a multi-site double-blind, placebo controlled, randomised controlled trial (RCT) of azithromycin in individuals aged 6-19 years with HCLD (defined as FEV1 z-score